摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

| 1443136-54-6

中文名称
——
中文别名
——
英文名称
——
英文别名
——
化学式
CAS
1443136-54-6
化学式
C20H21N5O6S
mdl
——
分子量
459.483
InChiKey
ACKOBJAKBWJCLE-RTEYEHBSSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.24
  • 重原子数:
    32.0
  • 可旋转键数:
    5.0
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.4
  • 拓扑面积:
    145.53
  • 氢给体数:
    2.0
  • 氢受体数:
    10.0

反应信息

  • 作为反应物:
    描述:
    4-二甲氨基吡啶 、 sodium hydroxide 作用下, 以 四氢呋喃吡啶甲醇二甲基亚砜 为溶剂, 反应 33.0h, 生成
    参考文献:
    名称:
    Synthesis and Properties of Isobicyclo-DNA
    摘要:
    AbstractWe present the synthesis of the isobicyclo‐DNA building blocks with the nucleobases A, C, G and T, as well as biophysical and biological properties of oligonucleotides derived thereof. The synthesis of the sugar part was achieved in 5 steps starting from a known intermediate of the tricyclo‐DNA synthesis. Dodecamers containing single isobicyclo‐thymidine incorporations, fully modified A‐ and T‐containing sequences, and fully modified oligonucleotides containing all four bases were synthesized and characterized. Isobicyclo‐DNA forms stable duplexes with natural nucleic acids with a pronounced preference for DNA over RNA as complements. The most stable duplexes, however, arise by self‐pairing. Isobicyclo‐DNA forms preferentially B‐DNA‐like duplexes with DNA and A‐like duplexes with complementary RNA as determined by circular dichroism (CD) spectroscopy. Self‐paired duplexes show a yet unknown structure, as judged from CD spectroscopy. Biochemical tests revealed that isobicyclo‐DNA is stable in fetal bovine serum and does not elicit RNaseH activity.
    DOI:
    10.1002/chem.201300487
  • 作为产物:
    描述:
    苯磺酸 、 sodium hydroxide 作用下, 以 四氢呋喃吡啶甲醇乙腈 为溶剂, 反应 5.0h, 生成
    参考文献:
    名称:
    Synthesis and Properties of Isobicyclo-DNA
    摘要:
    AbstractWe present the synthesis of the isobicyclo‐DNA building blocks with the nucleobases A, C, G and T, as well as biophysical and biological properties of oligonucleotides derived thereof. The synthesis of the sugar part was achieved in 5 steps starting from a known intermediate of the tricyclo‐DNA synthesis. Dodecamers containing single isobicyclo‐thymidine incorporations, fully modified A‐ and T‐containing sequences, and fully modified oligonucleotides containing all four bases were synthesized and characterized. Isobicyclo‐DNA forms stable duplexes with natural nucleic acids with a pronounced preference for DNA over RNA as complements. The most stable duplexes, however, arise by self‐pairing. Isobicyclo‐DNA forms preferentially B‐DNA‐like duplexes with DNA and A‐like duplexes with complementary RNA as determined by circular dichroism (CD) spectroscopy. Self‐paired duplexes show a yet unknown structure, as judged from CD spectroscopy. Biochemical tests revealed that isobicyclo‐DNA is stable in fetal bovine serum and does not elicit RNaseH activity.
    DOI:
    10.1002/chem.201300487
点击查看最新优质反应信息

同类化合物

鲁西他滨 化合物 T14195 [1,1'-联苯基]-2,3,3',4,4',5'-六醇 [(2R,3R,5S)-3-(氨基甲基)-5-(5-甲基-2,4-二氧代嘧啶-1-基)四氢呋喃-2-基]N-[[(2R,3S,5R)-3-羟基-5-(5-甲基-2,4-二氧代嘧啶-1-基)四氢呋喃-2-基]甲基]氨基甲酸酯 9-(2-S-苯甲基-5-脱氧-2-硫代五呋喃糖基)-9H-嘌呤-6-胺 5-脱氧胸苷 5-脱氧-5-[(碘乙酰基)氨基]-胸腺嘧啶脱氧核苷 5-碘-5-脱氧胸腺嘧啶脱氧核苷 5-氨基-5-脱氧胸腺嘧啶脱氧核苷 5-氨基-2,5-二脱氧腺苷酸 5-叠氮基-5-脱氧胸腺嘧啶脱氧核苷 5-三氟乙酰氨基-5-脱氧胸腺嘧啶脱氧核苷 5'-脱氧-5'氟胸苷 5'-脱氧-5'-氯胸苷-3'-(4-硝基苯基)硫代磷酸酯 5'-脱氧-5'-{[4-(甲硫基)苯胺基羰基]氨基}胸苷 5'-脱氧-5'-{[3-(甲硫基)苯胺基羰基]氨基}胸苷 5'-脱氧-5'-[4-苯基-(1,2,3)三唑-1-基]胸苷 5'-脱氧-5'-[4-(甲硫基)苯甲酰氨基]胸苷 5'-脱氧-5'-[4-(吡啶-3-基)-(1,2,3)三唑-1-基]胸苷 5'-脱氧-5'-[4-(4-氟苯基)-(1,2,3)三唑-1-基]胸苷 5'-脱氧-5'-<(苯氧基羰基)氨基>胸苷 5'-硫代-胸苷3',5'-二乙酸酯 5'-溴乙酰氨基-5'-脱氧胸苷 5'-氨基-5-碘-2',5'-二脱氧尿苷 4-氨基-1-((2R,3R,4R,5R)-4-((叔丁基二甲基硅烷基)氧基)-5-(( 2-氯-N-[[3-羟基-5-(5-甲基-2,4-二氧代嘧啶-1-基)四氢呋喃-2-基]甲基]乙酰胺 2-{[(2Z)-3,7-二甲基辛-2,6-二烯-1-基](亚硝基)氨基}乙醇 2,5-二脱氧腺苷 2',5'-二脱氧尿苷 1-[(2R,4S,5R)-4-羟基-5-(异氰基甲基)四氢呋喃-2-基]嘧啶-2,4-二酮 1-[(2R,4S,5R)-4-羟基-5-(异氰基甲基)四氢呋喃-2-基]-5-甲基嘧啶-2,4-二酮 1-(2,5-二脱氧-2-氟-β-D-呋喃阿拉伯糖基)嘧啶-2,4(1H,3H)-二酮 1-(2,5-二脱氧-2-氟-β-D-呋喃阿拉伯糖基)-5-碘嘧啶-2,4(1H,3H)-二酮 N-{9-[(2R,4S,5R)-5-Azidomethyl-4-(tert-butyl-diphenyl-silanyloxy)-tetrahydro-furan-2-yl]-9H-purin-6-yl}-benzamide (Z)-4-(1-(((2R,3S,5R)-3-hydroxy-5-(5-methyl-2,4-dioxo-3-((1-((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)-1H-1,2,3-triazol-4-yl)methyl)-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl)-1H-1,2,3-triazol-4-ylamino)-4-oxobutane-1,2-diyl dioleate 5'-[4-((1,2-distearoyl-sn-glycer-1-yl)methyl)-1H-1,2,3-triazol-1-yl]-N-3-propargylthymidine 5'-deoxy-5'-hydrazinothymidine hydrochloride N-<5'-Desoxy-thymidinyl-(5')>-phosphorsaeure-<β,β,β-trichlorethylester>-amid Acetic acid (2S,3S,5R)-2-fluoromethyl-5-(5-methyl-2-oxo-4-thioxo-3,4-dihydro-2H-pyrimidin-1-yl)-tetrahydro-furan-3-yl ester N-<5'-Desoxy-thymidinyl-(5')>-phosphorsaeure--amid N-<5'-Desoxy-thymidinyl-(5')>-phosphorsaeure-bis--amid N4-Benzoyl-5'-chlor-2',5'-dideoxycytidin 5'-(bromoacetamido)-2',5'-dideoxy-5-iodouridine 5'-[3-(3-methoxy-2-methyl-acryloyl)-ureido]-5'-deoxy-thymidine 3'-deoxy-5'- O-methyl-3'-(N-(L-p-methoxyphenylalanyl)amino)adenosine 1-(2-deoxy-2-fluoro-4-C-methyl-β-D-arabinofuranosyl)cytosine hydrochloride 5'-N-Isobutyloxycarbonyl-5'-amino-5'-deoxythymidin 4'-chloromethyl-2'-deoxy-2'-fluoro-3'-O-dodecanoylcytidine 3'-O-methylene-5'-deoxy-5'-thiothymidylyl-(3'->5')-N6-benzoyl-3'-O-tert-butyldimethylsilyl-2',5'-dideoxy-5'-thioadenosine